Stearoyl-CoA Desaturase 1 as a Therapeutic Biomarker: Focusing on Cancer Stem Cells

Int J Mol Sci. 2023 May 18;24(10):8951. doi: 10.3390/ijms24108951.

Abstract

The dysregulation of lipid metabolism and alterations in the ratio of monounsaturated fatty acids (MUFAs) to saturated fatty acids (SFAs) have been implicated in cancer progression and stemness. Stearoyl-CoA desaturase 1 (SCD1), an enzyme involved in lipid desaturation, is crucial in regulating this ratio and has been identified as an important regulator of cancer cell survival and progression. SCD1 converts SFAs into MUFAs and is important for maintaining membrane fluidity, cellular signaling, and gene expression. Many malignancies, including cancer stem cells, have been reported to exhibit high expression of SCD1. Therefore, targeting SCD1 may provide a novel therapeutic strategy for cancer treatment. In addition, the involvement of SCD1 in cancer stem cells has been observed in various types of cancer. Some natural products have the potential to inhibit SCD1 expression/activity, thereby suppressing cancer cell survival and self-renewal activity.

Keywords: SCD1; cancer progression; cancer stem cells; lipid metabolism; phytochemicals.

Publication types

  • Review

MeSH terms

  • Cell Survival
  • Fatty Acids / metabolism
  • Fatty Acids, Monounsaturated / metabolism
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Neoplastic Stem Cells / metabolism
  • Stearoyl-CoA Desaturase* / metabolism

Substances

  • Stearoyl-CoA Desaturase
  • Fatty Acids
  • Fatty Acids, Monounsaturated